About Biogen Inc

Biogen Inc. operates as a biotechnology company focused on discovering, developing, and delivering innovative therapies for neurological and neurodegenerative diseases. The company's specialization in complex neurological conditions has made BIIB stock price particularly volatile based on clinical trial results and regulatory outcomes.

Biogen's product portfolio includes treatments for multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy, addressing some of the most challenging medical conditions. The company's expertise in neuroscience has established it as a leader in developing treatments for diseases affecting the central nervous system.

The company's controversial Alzheimer's treatment Aduhelm has generated significant attention from patients, physicians, and investors, while its multiple sclerosis franchise continues to provide substantial revenue. Biogen's biosimilar products offer additional revenue streams while its pipeline focuses on innovative neurological treatments, affecting BIIB stock price movements.

Biogen's research collaborations with academic institutions and other biotechnology companies help advance understanding of neurological diseases while sharing development risks. The company's ability to successfully develop effective treatments for neurological conditions while navigating regulatory challenges remains critical for its long-term success and market valuation.